Medroxyprogesterone acetate exacerbates glutamate excitotoxicity
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
We previously demonstrated that progesterone functions as a neuroprotective agent whereas medroxyprogesterone acetate (MPA; Provera) does not. Moreover, MPA antagonized the neuroprotective and neurotrophic outcomes induced by 17beta-estradiol (E2). Towards developing effective hormone therapies for protection against neurodegeneration, we sought to determine whether formulation, chemical features or prevention versus treatment mode of exposure affected the outcome of MPA treatment in survival of primary hippocampal neurons. Results of these analyses indicated that both crystalline MPA and a pharmaceutical formulation (Depo-Provera) lacked neuroprotective efficacy, indicating that the effects were not dependent upon MPA formulation. Likewise, MPA in the prevention and treatment paradigms were equally ineffective at promoting neuronal survival, indicating that timing of MPA administration was not a factor. Further, the detrimental effects of MPA were not due to the presence of the acetate group, as medroxyprogesterone was as ineffective as MPA in promoting neuronal survival. Moreover, MPA pretreatment exacerbated neuron death induced by glutamate excitotoxicity as indicated by a 40% increase in neuron death determined by direct live/dead cell count and a commensurate increase in the number of positive cells by terminal deoxynucleotidyl transferase-mediated nick end-labeling. Collectively these results predict that the progestin formulation of hormone therapy will affect the vulnerability of the central nervous system to degenerative insults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valery (1995) · doi:10.1001/jama.1995.03520270033028 · Cited by 2,320
Neuroprotective effects of estrogens: potential mechanisms of action
Green, P. S., & Simpkins, J. W. (2000) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(00)00017-4 · Cited by 523
Cited by
Stanczyk, F. Z., Hapgood, J. P., Winer, S., & Mishell, D. R. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1008 · Cited by 429
Estrogen, Menopause, and the Aging Brain: How Basic Neuroscience Can Inform Hormone Therapy in Women
Morrison, J. H., Brinton, R. D., Schmidt, P. J., & Gore, A. C. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3369-06.2006 · Cited by 386
Self-citationMinireview: translational animal models of human menopause: challenges and emerging opportunities
Diaz Brinton, R. (2012) · Endocrinology · doi:10.1210/en.2012-1340 · Cited by 272
Neuroprotective strategies for retinal disease
Pardue, M. T., & Allen, R. S. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.02.002 · Cited by 237
“, 2003) and exacerbate excitotoxicity in neural tissue (Nilsen et al., 2006).”
Progesterone and Nestorone Facilitate Axon Remyelination: A Role for Progesterone Receptors
Hussain, R., El-Etr, M., Gaci, O., Rakotomamonjy, J., Macklin, W. B., Kumar, N., Sitruk-Ware, R., Schumacher, M., & Ghoumari, A. M. (2011) · Endocrinology · doi:10.1210/en.2011-1219 · Cited by 123
Metadata
- Authors
- Nilsen, J., Morales, A., & Brinton, R. D.
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2006-01
- Volume
- 22
- Issue
- 7
- Pages
- 355-361
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W1968489938
- Cited by
- 50
- References
- 2
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medroxyprogesterone acetate exacerbates glutamate excitotoxicity. https://app.cochat.ai/papers/10.1080/09513590600863337
- The paper
- Nilsen, J., Morales, A., & Brinton, R. D. (2006). Medroxyprogesterone acetate exacerbates glutamate excitotoxicity. Gynecological Endocrinology. https://doi.org/10.1080/09513590600863337
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.